The Effect of Vitamin C Supplementation on Gut Microbiota Composition and Function in Healthy Adults (VitaGut)

The Effect of Vitamin C Supplementation on Gut Microbiota Composition and Metabolic Activity in Healthy Adults

The aim of this dietary intervention study is to explore how vitamin C affects the bacteria that live in our gut. Vitamins are essential nutrients found in fruits and vegetables. Our bodies cannot make them on their own, but we need them to function correctly. Vitamins play various roles, including supporting the immune system and assisting with energy production. Some vitamins in our diet can reach the large intestine, where they may be used by gut bacteria to promote their growth. In this study, we aim to investigate how our gut bacteria interact with vitamin C and how this interaction affects their growth and activity.

For this study, participants will follow their habitual diet for one-week (run-in period), followed by two consecutive two-week supplementation periods in which they will first take a moderate dose (200 mg/day) and then a high-dose (1000 mg/day) of vitamin C. A final one-week period follow up period will involve a return to their habitual diet. Faecal, blood and urine samples will be collected at the start and end of each supplementation period to explore changes in gut microbiota composition, activity and markers of inflammation.

Study Overview

• Status: Recruiting
• Conditions: Gut Microbiota Diversity and Composition; Short Chain Fatty Acids Concentration in Stools
• Intervention / Treatment: Dietary supplement: Moderate Vitamin C dose (200 mg); Dietary supplement: High-dose vitamin C supplementation (1000 mg); Other: Habitual diet (run in period)

Detailed Description

This is a sequential dietary intervention trial exploring the effects of two doses of vitamin C supplementation on gut microbiota: a moderate, diet-achievable dose of 200 mg/day, and a high dose of 1000 mg/day, each given for two weeks. Primary outcomes will be gut microbiota activity (SCFA production) and composition while secondary exploratory outcomes will include systemic inflammation and gut barrier integrity markers. We anticipate that this pilot study will provide valuable insights into the dose-response effects of vitamin C and help define optimal intakes for promoting gut health.

Twenty-three healthy adults will be recruited from the Glasgow area, with all study visits taking place at the New Lister Building, University of Glasgow. Each participant will attend four study visits over six weeks.

The intervention includes:

• One-week run-in period (habitual diet)
• Two weeks of moderate-dose vitamin C (Vitamin C Chewable Tablet 200 mg, one tablet per day)
• Two weeks of high-dose vitamin C (Vitamin C Chewable Tablet 1000 mg, one tablet per day)
• One-week follow-up (habitual diet)

There will be no washout period between the study periods and participants will be instructed to maintain their usual diet and lifestyle throughout the trial.

Hypothesis Vitamin C supplementation will increase stool SCFAs, particularly butyrate, and beneficially modulate gut microbiota composition, systemic inflammation and gut barrier integrity in healthy adults.

Study schedule and sample collection:

• Visit 1 (Week 0): Baseline anthropometric measurements will be taken (height, weight, body composition); stool and urine sample collection will be arranged. Participants will follow habitual diet for one week (run-in period).
• Visit 2 (Week 1): Anthropometric measurements; stool sample, and fasted blood and urine samples will be collected. The participants will begin a moderate-dose vitamin C supplementation (Vitamin C Chewable Tablet 200mg, one tablet per day) for two weeks (moderate-dose period), in addition to their usual diet.
• Visit 3 (Week 3): Anthropometric measurements; stool sample, and fasted blood and urine samples will be collected. The participants will switch to a high-dose vitamin C supplementation (Vitamin C Chewable Tablet 1000mg, one tablet per day) for two weeks (high-dose period), in addition to their usual diet.
• Visit 4 (Week 5): Anthropometrics; stool sample, and fasted blood and urine samples will be collected. Participants will resume their habitual diet for one week (follow-up period).
• Follow up (Week 6): Final stool sample collected.

Three-day food diaries, Gastrointestinal Symptoms Rating Scale (GSRS) diary, and compliance tick sheets will be completed during the run-in, moderate-dose, and high-dose periods.

Sample size The sample size is based on anticipated effects on stool butyrate, a key SCFA expected to be modified by the intervention. Based on literature and our group's previous results, recruiting 20 healthy participants would provide 80% power (P=0.05) to detect a mean change of 4 μmol/g in stool butyrate (SD: 4.5 μmol/g). Allowing for 15% drop-out, a total of 23 participants will ensure adequate power.

• Study Type: Interventional
• Enrollment (Estimated): 23
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Raihana Halim; Phone Number: 07857 725347; Email: 2859495H@student.gla.ac.uk

Study Locations

• United Kingdom
  • Glasgow, United Kingdom, G31 2ER
    • Recruiting
    • New Lister Building, Glasgow Royal Infirmary, 10-16 Alexandra Parade, G31 2ER
    • Contact: Athanasios Koutsos Lecturer in Human Nutrition, PhD; Email: Athanasios.Koutsos@glasgow.ac.uk
    • Principal Investigator: Athanasios Koutsos, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy individuals aged 18-65 years with a BMI between 18.5-35 Kg/m2
• Self-reported good health with no chronic conditions requiring regular medical care
• Willing to provide blood, urine, and stool samples at multiple time points

Exclusion Criteria:

• Aged <18 or >65 years
• Smoking
• Chronic illness requiring regular medication or GP visits
• Current or recent medication affecting gut transit or digestion
• Major gastrointestinal surgery
• Pregnant or breastfeeding
• Regular use of pre/probiotics, vitamins, or minerals (unless willing to discontinue 2-4 weeks prior)
• Antibiotics in past 3 months
• Weight change >±2 kg in past month
• Participation in other research likely to interfere with this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Sequential vitamin C intervention; In this single-arm, sequential dietary intervention study, participants will follow their normal habitual diet for one week (run-in period) and then receive two different doses of vitamin C tablets over two consecutive 14-day periods: a moderate dose of 200 mg/day during the first period (2 weeks) and a high dose of 1000 mg/day during the second period (another 2 weeks). The study also includes one week post intervention follow up period (habitual diet) after the high vitamin C dose where participants return to their habitual diet without vitamin C supplementation

Dietary supplement: Moderate Vitamin C dose (200 mg); 200 mg of vitamin C provided as a chewable tablet, taken orally daily for two weeks; Dietary supplement: High-dose vitamin C supplementation (1000 mg); 1000 mg of Vitamin C provided as a chewable tablet, taken orally daily for two weeks; Other: Habitual diet (run in period); this is a run-in period where participants consume their habitual diet for one week

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Butyrate (Short Chain Fatty Acid)	Quantified in stool samples using Gas Chromatography	Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)
Short Chain Fatty Acids i.e. acetate, propionate, butyrate, total	Quantified in stool samples using Gas Chromatography	Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)
Stool microbiota composition analysis	16S rRNA gene amplicon sequencing from faecal DNA extracts	Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stool pH	pH meter	Baseline (Visit 1), Week 1 (Visit 2), Week 3 (Visit 3), Week 5 (Visit 4) and Week 6 (Visit 5)
Vitamin C in plasma	Using validated analytical techniques	Week 1 (Visit 2), Week 3 (Visit 3), and Week 5 (Visit 4)
Inflammatory markers	Using Elisa or multiplex assays	Week 1 (Visit 2), Week 3 (Visit 3), and Week 5 (Visit 4)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gut barrier function markers	Quantified in plasma using standard enzyme-linked immunosorbent assay.	Week 1 (Visit 2), Week 3 (Visit 3), and Week 5 (Visit 4)

Collaborators and Investigators

• Sponsor: University of Glasgow
• Collaborators: Professor Konstantinos Gerasimidis, University of Glasgow
• Investigators: Principal Investigator: Athanasios Koutsos, PhD, Human Nutrition, School of Medicine, College of Medical, Veterinary, and Life Sciences, University of Glasgow

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: December 18, 2025
• First Submitted That Met QC Criteria: January 30, 2026
• First Posted (Actual): February 4, 2026

Study Record Updates

• Last Update Posted (Actual): February 4, 2026
• Last Update Submitted That Met QC Criteria: January 30, 2026
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: gut microbiota; vitamin C; SCFA
• Additional Relevant MeSH Terms: Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena; Exercise; Locomotion; Running; Jogging
• Other Study ID Numbers: 200250024

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No